Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Hematologic malignancies are among the most common cancers, and understanding their
incidence and death is crucial for targeting prevention, clinical practice improvement, and …

Simple Summary Histone deacetylases (HDACs) are epigenetic regulators that influence
chromatin structure and gene transcription, but also the function of non-histone targets like …

Background Melanoma of the skin is the most dangerous skin cancer in the world, though
the numbers of reported new cases and melanoma-related deaths are low. Objective This …

Background Steady evolution of therapies has improved prognosis of patients with multiple
myeloma (MM) over the past two decades. Yet, knowledge about survival trends and causes …

Background The incidence of multiple myeloma (MM), a type of blood cancer affecting
monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient …

Myeloma is one of the most common types of haematological malignancies. We aimed to
investigate the incidence rates of myeloma by sex, race, age, and histological subgroups in …

A major obstacle to chemotherapeutic success in cancer treatment is the development of
drug resistance. This occurs when a tumour fails to reduce in size after treatment or when …

Background Multiple myeloma (MM) is the second most common haematologic malignancy,
presenting a great disease burden on the general population; however, the quality of care of …

Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …